Breaking News Instant updates and real-time market news.

FOLD

Amicus

$8.32

-0.58 (-6.52%)

17:17
11/28/16
11/28
17:17
11/28/16
17:17

Amicus to pursue more migalastat data as FDA rules out quick path

Amicus Therapeutics (FOLD) plunged in after-hours trading after ruling out accelerated approval for its migalastat product and confirming the need for additional data. AMICUS SAYS MORE DATA NEEDED: In a press release shortly after market close, Amicus detailed its "planned regulatory pathway to collect additional data to support full approval" of migalastat: "Following several collaborative discussions with the FDA, including the receipt of final written minutes from an in-person Type B meeting, the company plans to collect additional data on gastrointestinal symptoms in Fabry patients who have an amenable mutation. Key elements of the additional data generation... may include: Randomized, 12-month, placebo-controlled pivotal 'cross-over' study in treatment naive Fabry patients who have an amenable mutation and GI symptoms. Crossover study design provides sufficient powering with a small number of patients, ~35 patients planned. Primary endpoint to assess diarrhea based upon established FDA irritable bowel syndrome guidance." Amicus noted it is working with the FDA to finalize the clinical protocol and plans to initiate enrollment in 2017, with data expected in 2019. The company also disclosed that "during its review of the briefing document submitted and in discussions with Amicus, the FDA acknowledged that significant unmet medical need exists in Fabry disease. The agency also indicated that kidney globotriaosylceramide is currently not considered a basis for an accelerated approval under Subpart H." Weighing in on the news, CEO John Crowley stated, "While we believe that the totality of the data from our studies with migalastat support the submission of a new drug application today, we acknowledge the FDA's position that accelerated approval based on kidney GL-3 reduction is not currently an option... FDA has been flexible in allowing a crossover design and in our use of established GI endpoints to measure clinical benefit in Fabry patients. We are fully committed to the additional work necessary to move migalastat toward approval." PRICE ACTION: Shares of Amicus are down 27.76% to $6.01 in post-market trading.

FOLD Amicus
$8.32

-0.58 (-6.52%)

06/14/16
LEER
06/14/16
NO CHANGE
Target $19
LEER
Outperform
Protalix development encouraging for Amicus Galafold, says Leerink
Leerink analyst Joseph Schwartz is "incrementally encouraged" by the news that Protalix (PLX) reached an agreement with the FDA to advance its Fabry ERT into a pivotal trial, just before Amicus' (FOLD) meeting with the agency to discuss a regulatory path for its Galafold. Amicus was poised to emphasize non-renal data in the upcoming FDA meeting, but now the company has "another way to win" by using renal data, the analyst tells investors in a research note. Schwartz now assigns a 33% probability for Galafold. The analyst reiterates an Outperform rating on Amicus' stock and raised his price target on the shares to $19 from $17.
07/20/16
JPMS
07/20/16
NO CHANGE
Target $13
JPMS
Overweight
Amicus risk/reward 'compelling' at current levels, says JPMorgan
JPMorgan analyst Anupam Rama views the risk/reward for shares of Amicus Therapeutics at current levels as "compelling." After declining 39% year-to-date, Amicus is essentially only pricing in outside the U.S. Galafold sales in Fabry disease plus cash, Rama tells investors in a research note. Very little credit is being given to the company's U.S. migalastat, Zorblisa or the Pompe program, which all have events in the second half of 2016, the analyst contends. Rama thinks only one of the three need to hit for the stock to trade "materially higher," with upside ranging from 20%-100%-plus on a single success, and "meaningfully more upside" potential on multiple positive updates. Rama reiterates an Overweight rating on Amicus with a $13 price target.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

CBI

CB&I

$20.79

0.7683 (3.84%)

13:40
06/28/17
06/28
13:40
06/28/17
13:40
Options
Call buyer opens a big new position in Chicago Bridge and Iron »

Call buyer opens a big…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
06/28/17
06/28
13:40
06/28/17
13:40
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

EGO

Eldorado Gold

$2.72

-0.1 (-3.55%)

13:37
06/28/17
06/28
13:37
06/28/17
13:37
Downgrade
Eldorado Gold rating change  »

Eldorado Gold downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

GOOS

Canada Goose

$20.60

-0.49 (-2.32%)

13:30
06/28/17
06/28
13:30
06/28/17
13:30
Upgrade
Canada Goose rating change  »

Canada Goose upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

13:25
06/28/17
06/28
13:25
06/28/17
13:25
Conference/Events
JPMorgan life sciences analyst holds an analyst/industry conference call »

Life Science Tools &…

MU

Micron

$31.66

-0.84 (-2.58%)

13:24
06/28/17
06/28
13:24
06/28/17
13:24
Hot Stocks
Nanya Technology lowers Micron stake to 4.17% with recent sale of 11.6M shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 29

    Aug

BPY

Brookfield Property

$24.08

0.34 (1.43%)

13:22
06/28/17
06/28
13:22
06/28/17
13:22
Conference/Events
Brookfield Property management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

13:20
06/28/17
06/28
13:20
06/28/17
13:20
General news
Treasury's $28 B 7-year auction results fell to the soft side »

Treasury's $28 B…

BPOP

Popular

$39.33

0.16 (0.41%)

13:19
06/28/17
06/28
13:19
06/28/17
13:19
Conference/Events
Popular management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 26

    Sep

  • 27

    Sep

$NSD

NASDAQ Market Internals

13:17
06/28/17
06/28
13:17
06/28/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$42.30

0.4 (0.95%)

13:16
06/28/17
06/28
13:16
06/28/17
13:16
Conference/Events
Methanex management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

$NYE

NYSE Market Internals

13:16
06/28/17
06/28
13:16
06/28/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
06/28/17
06/28
13:15
06/28/17
13:15
General news
Treasury Action: intermediate yields ticked higher »

Treasury Action:…

CS

Credit Suisse

$14.45

0.2 (1.40%)

13:14
06/28/17
06/28
13:14
06/28/17
13:14
Syndicate
Breaking Syndicate news story on Credit Suisse »

Credit Suisse files $85B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$6.54

-0.28 (-4.11%)

13:12
06/28/17
06/28
13:12
06/28/17
13:12
Conference/Events
ImmunoGen management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

VZ

Verizon

$44.85

0.005 (0.01%)

, GOOG

Alphabet

$927.33

-24.94 (-2.62%)

13:09
06/28/17
06/28
13:09
06/28/17
13:09
Periodicals
Verizon explores pooling consumer data with other wireless firms, BI says »

After closing its…

VZ

Verizon

$44.85

0.005 (0.01%)

GOOG

Alphabet

$927.33

-24.94 (-2.62%)

GOOGL

Alphabet Class A

$948.09

-24 (-2.47%)

FB

Facebook

$150.58

-3.01 (-1.96%)

TMUS

T-Mobile

$61.01

-2.14 (-3.39%)

S

Sprint

$8.14

-0.04 (-0.49%)

VOD

Vodafone

$28.65

-0.145 (-0.50%)

TEF

Telefonica

$10.53

-0.1 (-0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 27

    Jul

  • 03

    Aug

MIC

Macquarie Infrastructure

$79.18

0.8299 (1.06%)

13:09
06/28/17
06/28
13:09
06/28/17
13:09
Conference/Events
Macquarie Infrastructure management to meet with RBC Capital »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 18

    Jul

  • 19

    Jul

13:05
06/28/17
06/28
13:05
06/28/17
13:05
General news
7-Yr Note Auction Coupon Rate data reported »

7-Yr Note Auction Coupon…

13:05
06/28/17
06/28
13:05
06/28/17
13:05
General news
7-Yr Note Auction Total Amount data reported »

7-Yr Note Auction Total…

13:05
06/28/17
06/28
13:05
06/28/17
13:05
General news
Treasury Option Action: bullish 10-year positioning »

Treasury Option Action:…

MTCH

Match Group

$17.50

-0.295 (-1.66%)

13:04
06/28/17
06/28
13:04
06/28/17
13:04
Hot Stocks
Tinder introduces Tinder Gold premium service »

Match Group's Tinder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$4.04

0.2989 (7.99%)

, WBA

Walgreens Boots Alliance

$77.26

-0.27 (-0.35%)

13:02
06/28/17
06/28
13:02
06/28/17
13:02
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

RAD

Rite Aid

$4.04

0.2989 (7.99%)

WBA

Walgreens Boots Alliance

$77.26

-0.27 (-0.35%)

MKC

McCormick

$98.40

-0.135 (-0.14%)

LNN

Lindsay

$87.92

1.32 (1.52%)

GBX

Greenbrier

$50.15

0.7 (1.42%)

CAG

Conagra Brands

$37.53

0.525 (1.42%)

STZ

Constellation Brands

$183.93

1.65 (0.91%)

AYI

Acuity Brands

$180.03

4.695 (2.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 07

    Jul

GOOG

Alphabet

$927.33

-24.94 (-2.62%)

, GOOGL

Alphabet Class A

$948.09

-24 (-2.47%)

13:02
06/28/17
06/28
13:02
06/28/17
13:02
Periodicals
Alphabet sought to sell Nest last year, Reuters reports »

At a certain point in…

GOOG

Alphabet

$927.33

-24.94 (-2.62%)

GOOGL

Alphabet Class A

$948.09

-24 (-2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

PIR

Pier 1 Imports

$5.42

0.0799 (1.50%)

, SHLM

A. Schulman

$27.50

-1.05 (-3.68%)

13:02
06/28/17
06/28
13:02
06/28/17
13:02
Earnings
Notable companies reporting after market close »

Notable companies…

PIR

Pier 1 Imports

$5.42

0.0799 (1.50%)

SHLM

A. Schulman

$27.50

-1.05 (-3.68%)

PRGS

Progress Software

$30.08

-0.16 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

AMZN

Amazon.com

$976.78

-17.2 (-1.73%)

, GOOG

Alphabet

$927.33

-24.94 (-2.62%)

13:00
06/28/17
06/28
13:00
06/28/17
13:00
Hot Stocks
Best Buy to launch Amazon Alexa, Google Home 'experiences' in 700 stores »

Best Buy (BBY) announced…

AMZN

Amazon.com

$976.78

-17.2 (-1.73%)

GOOG

Alphabet

$927.33

-24.94 (-2.62%)

GOOGL

Alphabet Class A

$948.09

-24 (-2.47%)

BBY

Best Buy

$56.96

0.78 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 29

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.